Search Results

Hyphens Pharma International Limited is pleased to announce that its subsidiary, Hyphens Pharma Pte. Ltd., has entered into an exclusive license, supply and commercialisation agreement with MC2 Therapeutics for the exclusive rights to register and commercialise Wynzora® Cream and all future product extensions and/or improvements for the topical treatment of plaque psoriasis in the 10 ASEAN countries.

MC10, Inc., the developer of BioStamp nPoint, an end-to-end system for physiological data collection and analytics, announced today a collaboration with the University of Vermont, a leading academic research institution.

MC10, Inc., creators of the innovative wearable device BioStamp nPoint, and the University of Rochester announced today a collaboration on advancing methods of assessing Central Nervous System (CNS) diseases

This collaboration bridges MC10’s expertise in wearable health solutions, DevSci’s leading-edge research on how the prenatal environment shapes early brain and behavioral development, and Lurie Children’s expertise in research at the maternal-fetal interface.

As part of the collaboration, LabCorp has also made an equity investment into MC10.

The study is sponsored by Neurocrine Biosciences and conducted in collaboration with the Huntington Study Group.

2023 marked the most bankruptcies in biopharma in more than a decade, with 14 companies filing for Chapter 11 protection. The number remained high in 2024.